Endocyte stock: buy or sell?
December 20th, 2018
Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States.
Should I buy Endocyte stock?Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Trading strategies are meant for helping you in the decision process of what stocks to choose and when is the best time to buy them. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
Currently, 2 buy setups are elegible for Endocyte stock now:
|New all-time high||Yes|
|New 52 week high||Yes|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Endocyte stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.Unfortunately, we couldn't find any rating for ECYT stock for the last month.
Endocyte stock analysis
After several days of continuous hikes in past weeks, Endocyte stayed steady -0.04% to $23.99.
After marking all time highs on December, Endocyte stayed constant -0.04% on December to $23.99. ECYT shows a sign of strength in the short-term after finally breaking out above $23.94 on December and marking a new rising bottom. Since last October when ECYT stock price broke up the SMA100d line, it gained $8.43 (54.18%). Even closing lower, the session peaked to new all time high beating yesterday highs.
Endocyte shares reached new all time highs again this week, marking to $24.00. Shares ended at $23.99 and inched 0.63% during the week. With this, it's been 4 climbing weeks in a row, soaring a 1.65%.
Endocyte stock is trading in the range of its last top and last bottom. Loosing would mean breaking the current uptrend. Breakdowns under last bottom are selling point signals for some trading strategies. By mid October 2018 ECYT price bounced up over the SMA of 20 weeks that acted as support stopping new slides.
Endocyte stock price history
Endocyte IPO was on March 5th, 2018 at $6.39 per share1. Since then, ECYT stock surged a 275.40%, with an average of 275.40% per year. If you had invested $1,000 in Endocyte stock in 2018, it would worth $2,754.00 today.
1: Adjusted price after possible price splits or reverse-splits.
Endocyte stock historical price chart
ECYT stock reached all-time highs on December with a price of $24.00.
Endocyte stock price targetPredicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. You should not follow the analysts' ECYT stock price predictions in the hope that they will be met as they may be wrong and not met. For the last 30 days we have not detected any price forecast for Endocyte stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per ShareEndocyte presented fine results for 2018-Q3 on November. Endocyte gained Earnings per Share (EPS) by 6.30%, beating analysts of $-0.16. Endocyte posted $-0.17.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2016, last anual revenues report draw a tight move of 0.00% to $0.07 M USD. On the other hand, its income margin (compared to sales) plunged to -78,663.14%, that is $-55.06 million. Endocyte fiscal year ends in December, and to compare its evolution since then, we estimate annual sales and income figures by adding results from the last 4 quarters. This is called TTM (or Twelve Trailing Months). So, Endocyte TTM sales up to September 2018 were $0.13 and earnings $-41.34 million dollars. When comparing this TTM figures with the last reported annuality, we can esteem Endocyte business evolution since December 2017: Annual revenues up to September, compared to lastest yearly report, skyrocketed an outstanding 83.82%. Regarding profit margin, Endocyte boosted 46,536.65% to -78,663.14%
|2013||$65 M||-||$-18.03 M-27.8%||-|
|2014||$70 M||8.45%||$5.46 M7.8%||-130.28%|
|2015||$0.07 M||-99.90%||$-41.27 M-58956.7%||-855.93%|
|2016||$0.07 M||0.00%||$-43.89 M-62696.6%||6.34%|
|2017||$0.07 M||0.00%||$-55.06 M-78663.1%||25.47%|
|TTM||$0.13 M||83.82%||$-41.34 M-32126.5%||-24.93%|
Quarterly financial resultsEndocyte reported $0.09 million in revenues for 2018-Q3, a 493.54% up compared to previous quarter. Reported quarter earnings marked $-12.61 M with a profit margin of -14,684.64%. Profit margin skyrocketed a 65,264.20% compared to previous quarter when profit margin was -79,948.84%. When comparing turnover to same quarter last year, Endocyte sales marked a super good growth and boosted a 164.17%.
|2016-Q4||$0.01 M||-||$-11.07 M-92250.0%||-|
|2017-Q1||$0.01 M||4.17%||$-11.49 M-91920.0%||3.79%|
|2017-Q2||$0.01 M||0.00%||$-11.74 M-93920.0%||2.18%|
|2017-Q3||$0.03 M||160.00%||$-23.27 M-71590.2%||98.18%|
|2017-Q4||$0.01 M||-61.54%||$-8.56 M-68512.2%||-63.19%|
|2018-Q1||$0.02 M||26.84%||$-8.60 M-54258.3%||0.45%|
|2018-Q2||$0.01 M||-8.77%||$-11.56 M-79948.8%||34.43%|
|2018-Q3||$0.09 M||493.54%||$-12.61 M-14684.6%||9.02%|
Endocyte ownershipWhen you are planning to invest in shares of a stock, it's always worth to review its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Endocyte, of all outstanding shares are owned by its staff.
The following table compares ownership indicators for other stocks related to Endocyte:
|Market cap||$0.0 M|
|Total shares||0.0 M|
|Float shares||0.0 M|
|- Institutional holdings (%)||0.0%|
|- Insider holdings (%)||0.0%|
|Shares in short selling||0.0%|
|Thursday, December 20th, 2018|
|Day range||$23.99 - $24.00|
|Average true range||$0.09|
|50d mov avg||$22.67|
|100d mov avg||$20.08|
|200d mov avg||$0.00|
Endocyte performanceTo better understand Endocyte performance you must becnhmark its gains with other related stocks in same sector or industry. We compared Endocyte against in the following table: